Skip to main content
. 2021 Feb 28;9(3):243. doi: 10.3390/biomedicines9030243

Figure 6.

Figure 6

Differential miRNA expression from circulation EVs from patients with different responses to EGFR-TKI treatment corresponded to that from cell lines EVs. (A) Flowchart showing the collection of blood exosomal miRNAs from patients with different responses to EGFR-TKIs. Identification of differentially expressed miRNAs in responders and nonresponders to EGFR-TKIs. (B) Identification of miRNAs that are both differentially expressed between responders and nonresponders to EGFR-TKIs and between EVs from PC9 cells and CL1-5 cells. (C) CL1-5 cells were transfected with miR-200c and treated with gefitinib, and the pStat3, Stat3, pAkt, Akt, pErk, and Erk protein levels were detected with a Western blot kit. (D) The changes in apoptosis-related proteins, including caspase-3 and caspase-9, after miR-200c transfection with gefitinib treatment were determined using Western blotting. The combination of miR-200c and treatment with gefitinib affected EMT-related proteins (E-cadherin and Zeb1) and BIM protein. (E) Histograms showing the enhanced efficacy of gefitinib in CL1-5 cells transiently transfected with miR-200c as determined by MTT assays (* p < 0.05, ** p < 0.01, *** p < 0.005).